|1.||Voziyan, Paul A: 6 articles (01/2008 - 11/2003)|
|2.||Hudson, Billy G: 6 articles (01/2008 - 11/2003)|
|3.||Nagai, Ryoji: 4 articles (02/2014 - 04/2008)|
|4.||Tomino, Yasuhiko: 4 articles (01/2012 - 02/2007)|
|5.||Chetyrkin, Sergei V: 4 articles (01/2008 - 01/2005)|
|6.||Yamagishi, S: 4 articles (01/2006 - 01/2005)|
|7.||Nakamura, K: 4 articles (01/2006 - 01/2005)|
|8.||Alderson, Nathan L: 4 articles (11/2003 - 03/2002)|
|9.||Baynes, John W: 4 articles (11/2003 - 03/2002)|
|10.||Thorpe, Suzanne R: 4 articles (11/2003 - 03/2002)|
01/01/2012 - "Pyridoxamine ameliorates lipid peroxidation and insulin resistance in KK-Ay mice. "
09/01/2010 - "Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice."
09/01/2010 - "Therefore, in this study, we examined whether pyridoxamine, an inhibitor of AGE formation could ameliorate insulin resistance in KK-A(y) mice, a model animal of obese, type 2 diabetes. "
02/01/2009 - "It appears that pyridoxamine ameliorated lipid peroxidation and insulin resistance in KK-A(y)/Ta mice. "
04/10/2009 - "The advanced glycation end product inhibitor pyridoxamine (PYR) and the antioxidant alpha-lipoic acid (LA) interact to ameliorate insulin resistance in obese Zucker rats following short-term (6-week) treatment. "
|2.||Diabetic Nephropathies (Diabetic Nephropathy)
01/01/2012 - "Of note, pyridoxamine has also shown promise in the treatment of diabetic nephropathy if started early in the disease course. "
02/01/2009 - "The objective of the present study was to examine the pleiotropic effects of pyridoxamine, especially CD36 expression in KK-A(y)/Ta mice with type 2 diabetic nephropathy. "
01/01/2015 - "Pyridoxamine dihydrochloride (Pyridorin™) blocks pathogenic oxidative pathways in the progression of diabetic nephropathy. "
01/01/2015 - "Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study."
04/01/2014 - "In this review, the authors explore pyridoxamine and other emerging therapeutic agents in the battle against diabetic nephropathy. "
07/20/2015 - "Pyridoxamine (PM) is a prospective drug for the treatment of diabetic complications. "
02/01/2009 - "Pyridoxamine inhibits the development of diabetic complications. "
02/01/2009 - "Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice."
10/01/2008 - "The AGE inhibitor pyridoxamine (PM) prevents irreversible protein glycation, thereby reducing various diabetic complications. "
11/21/2003 - "We have investigated the conversion of protein-Amadori intermediate to protein-AGE and the mechanism of its inhibition by pyridoxamine (PM), a potent AGE inhibitor that has been shown to prevent diabetic complications in animal models. "
12/26/2006 - "These results demonstrate the utility of pyridoxamine and lipophilic pyridoxamine analogues to assess the potential contributions of isoketals and levuglandins in oxidant injury and inflammation and suggest their potential utility as pharmaceutical agents in these conditions."
07/01/2007 - "We demonstrate that although aminoguanidine, pyridoxamine, and BMP-7 significantly inhibit glomerular lesions, BMP-7 is most effective in the inhibition of tubular inflammation and tubulointerstitial fibrosis in these mice. "
02/01/2011 - "A number of novel therapeutic agents have also been tested in db/db mice, including inhibitors of inflammation (chemokine receptor antagonists, anti-CCL2 RNA aptamer, anti-c-fms antibody); oxidative stress (oxykine, biliverdin); the renin-angiotensin-aldosterone system (aliskiren, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone); advanced glycation end products (AGE; pyridoxamine, alagebrium, soluble AGE receptor); angiogenesis (NM-3, anti-CXCL12 RNA aptamer, soluble Flt-1); lipid accumulation (statins, farnesoid X receptor agonists, Omacor); intracellular signaling pathways (PKC-β or JNK inhibitors); and fibrosis [transforming growth factor (TGF)-β antibody, TGF-βR kinase inhibitor, soluble betaglycan, SMP-534, CTGF-antisense oligonucleotide, mutant PAI-1, pirfenidone], which have identified potential therapeutic targets for clinical translation. "
|5.||Primary Hyperoxaluria (Oxaluria, Primary)
01/01/2005 - "These results, coupled with favorable toxicity profiles of pyridoxamine in humans, show promise for therapeutic use of pyridoxamine in primary hyperoxaluria and other kidney stone diseases."
11/01/2005 - "Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria."
01/01/2005 - "Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria."
10/01/2015 - "Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I."
|3.||Blood Glucose (Blood Sugar)
|4.||Bone Morphogenetic Protein 7
|7.||Vitamin B 6
|8.||Advanced Glycosylation End Products
|10.||Pyridoxal Phosphate (Pyridoxal 5 Phosphate)